1025 ET - Danaher falls after guiding for core revenue, which strips out foreign currency translation, acquisitions and divested product lines, to rise just 3% in 2025. The results are disappointing, given that demand was expected to show some improvement in the current quarter, Edward Jones analyst John Boylan says in a research note. Still, he says he can't fault the company's conservatism after a tough run of quarters. Demand should eventually return, as drug companies often need Danaher's products to discover and manufacture drugs, so long-term investors will be rewarded for their patience, Boylan says. Shares drop 7.2% to $230.01. (dean.seal@wsj.com)
(END) Dow Jones Newswires
January 29, 2025 10:25 ET (15:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.